Pharsight

1. List of Acular Ls drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207215	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8906950	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8946281	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8648107	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8377982	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US9216167	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8541463	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8377982 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2024 (1 year, 9 months from now)
US8541463 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2024 (1 year, 9 months from now)
US8207215 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2024 (1 year, 9 months from now)
US8008338 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2027 (4 years from now)

Market Authorisation Date: 30 May, 2003

Treatment: A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning; A method of treating ocular pain; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging; A method of treating or preventing ocular pain in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.004	28 Jan, 2005	1	05 Nov, 2009	05 May, 2011	Extinguished

Strength	Dosage	Availability
0.4%	SOLUTION/DROPS;OPHTHALMIC	Prescription

2. List of Acuvail drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7842714	ALLERGAN	Ketorolac tromethamine compositions for treating ocular pain	Aug, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952	ALLERGAN	Compositions for delivery of therapeutics into the eyes and methods for making and using same	Aug, 2024 (1 year, 6 months from now)
US9192571	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Mar, 2028 (5 years from now)
US8512717	ALLERGAN	Compositions for delivery of therapeutics into the eyes and methods for making and using same	Mar, 2028 (5 years from now)